Apeiron Investment, Peter Thiel and Catalio Capital Management led a $125m Series C round in ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications. Additional investors include Future Ventures, Galaxy Investment Partners, Falcon Edge Capital and Pura Vida. "We are grateful to have the strong support of both new and existing investors, comprised of forward-thinking individuals that share in our belief that innovation in mental healthcare is urgently needed and possible. We believe that our psychedelic and non-psychedelic compounds have compelling therapeutic promise based upon a growing body of scientific evidence. This round of funding is another step towards our vision to effectively treat and ultimately prevent mental health disorders, bridging the gap between what the mental health system currently provides and what patients need," Florian Brand, ATAI Life Sciences CEO & Co-Founder.